APA (7th ed.) Citation

T, v. M., MJ, K., G, I., G, H., P, M., AM, G., . . . ML, W. (2026). Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: Primary analysis of ZUMA-2 cohort 3. Blood, 147(12), 1302. https://doi.org/10.1182/blood.2025029734

Chicago Style (17th ed.) Citation

T, van Meerten, et al. "Brexucabtagene Autoleucel for BTKi-naive Relapsed/refractory Mantle Cell Lymphoma: Primary Analysis of ZUMA-2 Cohort 3." Blood 147, no. 12 (2026): 1302. https://doi.org/10.1182/blood.2025029734.

MLA (9th ed.) Citation

T, van Meerten, et al. "Brexucabtagene Autoleucel for BTKi-naive Relapsed/refractory Mantle Cell Lymphoma: Primary Analysis of ZUMA-2 Cohort 3." Blood, vol. 147, no. 12, 2026, p. 1302, https://doi.org/10.1182/blood.2025029734.